BeOne Medicines files STAR Interim Report; details R&D spend by key products for H1 2025

BeOne Medicines Ltd.

Total R&D expenses $1,007M for H1 2025, up from $915M in H1 2024.
BCL2 inhibitor (BGB-11417) R&D spending surged to $94M from $39M YoY.
CDAC (BGB-16673) R&D increased to $27M from $6M; CDK4 (BGB-43395) to $10M from $2M.
Zanubrutinib R&D flat at $63M; Tislelizumab R&D up to $40M from $34M.
Filing includes PRC GAAP vs U.S. GAAP reconciliation for share-based comp, income taxes, leasing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.